Experts explore the potential of invasive disease-free survival as a key metric in breast cancer trials, aiming to accelerate treatment approvals.
Stephanie L. Graff, MD
Stephanie L. Graff, MD, FACP, FASCO, is the director of the Breast Oncology Program at Brown University Health Cancer Institute, and co-leader of the Breast Cancer Translational Research Disease Group.
Articles by Stephanie L. Graff, MD
Stephanie L. Graff, MD, discusses what a community oncologist should know about her presentation on the Signatera assay in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer after adjuvant abemaciclib and endocrine therapy.